Abstract:Abstract Background: Adenosquamous carcinoma of the pancreas (PASC) is a mixed tumor type which contains squamous cell carcinoma and also ductal adenocarcinoma components. PASC is a rare type representing about 1-4% of the total incidence. Due to the rarity of this malignancy, limited genomic data have been performed. In this study, we analyzed the genomic alterations and clinical signatures of PASC. Materials and Methods: Formalin fixed, paraffin embedded (FFPE) tumor tissues and matched blood samples were collected for targeted next-generation sequencing (NGS) assay at OrigiMed (Shanghai, China), a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Genomic alterations including single base substitution, indel, copy number variations, gene fusions and rearrangement were assessed. Tumor mutational burden (TMB) was also analyzed by NGS algorithm. Alterations in homologous recombination repair (HRR) with PASC were analyzed. Results: In total, 31 PASC patients were recruited included 15 females (48.4%) and 16 males (51.6%) with a media age of 59 years old (range 35-78). A total of 32% (10/31) of patients possessed a confirmed cancer-related family history. The most commonly altered genes were KRAS (97%), TP53 (77%), CDKN2A (35%), SMAD4 (23%), FAT3 (13%), CIC (10%) and SPTA1 (10%). The KEGG pathway analysis revealed that those top mutated genes significantly associated with MAPK signaling pathway. 42% (13/31) of the patients had one or more actionable genomic alterations, including BRCA2, STK11, CDKN2A/B, FGFR and PTEN. Germline mutations were identified in 4 patients (13%), including BRCA2 (2/4), SPINK1 (1/4), FANCA (1/4). The most common mutational type was substitution/Indel (56%), followed by truncation (20%) and gene amplification (17%). Three (10%) patients had at least one mutation in HRR genes, including BRCA2 (2/3) and CHEK2 (1/3).The median TMB of patients with PASC was 3.2 muts/Mb (range, 0.5-9.3 muts/Mb). Patients with STK11 alterations had lower value of TMB than STK11 wild type (median TMB 0.85 vs. 3.37 muts/Mb, respectively, P <0.05). In addition, patients with HRR mutations had a significantly higher TMB value than HRR wild type (7.73 vs. 2.73 muts/Mb, respectively, P <0.01). Conclusion: Our study revealed the genomic profiling of the largest sample size of Chinese PASC patients so far. 42% (13/31) of the patients had one or more actionable genomic alterations. HRR pathway alterations are relatively frequent (10%) in PASC and consideration for biomarker-enriched clinical trials with PARP, immune checkpoint inhibitors, and novel combinations are warranted. Citation Format: Zheng Wang, Xue Yang, Wei Li, Zheng Wu, Qingyong Ma, Xiaofang Qi, Juan Zhao. Genomic profiling of Chinese adenosquamous carcinoma of the pancreas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2659.

Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes

The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer

Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer

Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort

Abstract 4607: G1/S Transition-Related Gene Mutations Associated with Survival of Hepatocellular Carcinoma Patients

The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients

Prognostic Value of Important Driver Gene Mutations in Patients with Radical Resection of Pancreatic Cancer

Identification of Copy Number Variation-Driven Molecular Subtypes in Pancreatic Adenocarcinoma of Chinese Cohort

Homologous recombination repair gene mutations in Chinese pancreatic ductal adenocarcinoma patients.

Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy

1541P the Genomic Features of Chinese Pancreatic Adenocarcinoma and the Implications for Therapy

The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients with Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Cancer Genomes Reveal Aberrations in Axon Guidance Pathway Genes

Comparative Genomic Analysis of Head and Body/tail of Pancreatic Ductal Adenocarcinoma at Early and Late Stages.

Main Driver Genes and BRCA Mutation in Chinese Patients with Pancreatic Adenocarcinoma.

Comparative genomic analysis of head and body/tail of pancreatic ductal adenocarcinoma at early and late stages

Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications

Abstract 2659: Genomic Profiling of Chinese Adenosquamous Carcinoma of the Pancreas

Association of Alterations in Main Driver Genes with Outcomes of Patients with Resected Pancreatic Ductal Adenocarcinoma

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan